

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jinxin Fertility Group Limited

錦欣生殖醫療集團有限公司*

(Incorporated under the laws of the Cayman Islands with limited liability)

(Stock Code: 1951)

POSITIVE PROFIT ALERT

The announcement is made by Jinxin Fertility Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (“**IFRS**”)) for the year ended December 31, 2023 (“**FY2023**”), it is expected that the net profit and adjusted net profit (non-IFRS measure) of the Group for FY2023 will increase by no less than 192% and 71% as compared to that of the Group for the year ended December 31, 2022, respectively. Such increase was primarily attributable to (i) the recovery and growth experienced by the Group across its assisted reproductive medical facilities after the cessation of the COVID-19 pandemic, including an increase in the number of patient visits and in vitro fertilization (IVF) treatment cycles; and (ii) the optimizing and strengthening of the operational efficiency of the Group and its medical facilities.

The Company is still in the process of finalizing the annual results of the Group for FY2023. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for FY2023, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit and risk management committee of the Board. Shareholders and potential investors of the Company should refer to the annual results announcement of the Group for FY2023, which is expected to be published by the end of March 2024.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Jinxin Fertility Group Limited
Zhong Yong
Chairman

Hong Kong, March 15, 2024

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Zhong Yong, Dr. John G. Wilcox, Mr. Dong Yang, Ms. Lyu Rong and Dr. Geng Lihong, as executive Directors; Mr. Fang Min, Ms. Hu Zhe and Ms. Yan Xiaoqing, as non-executive Directors; and Dr. Chong Yat Keung, Mr. Li Jianwei, Mr. Wang Xiaobo and Mr. Ye Changqing, as independent non-executive Directors.

* *for identification purposes only*